10.1 C
London
Sunday, December 10, 2023

Emerging Growth Conference 66 January 10 & 11 - Register now

ASX Commentary

Discussion about stocks trading on the Australian Stock Exchange ASX from professionals in the Australian stock and investing profession

$1.87 million raised in oversubscribed Shortfall facility

MELBOURNE Australia, 13 July 2023: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is pleased...

New AD-214 Data Links Phase I Results With Efficacy; De-Risks Clinical Dosing Schedule

Key points: • New data favourably links AD-214 preclinical animal studies and Phase I human clinical trial results to provide important dose frequency insights • AD-214 is designed to...

AdAlta (ASX: 1AD) IMPORTANT PHASE I EXTENSION CLINICAL STUDY OF AD-214 APPROVED

29 June 2023 ASX Announcement IMPORTANT PHASE I EXTENSION CLINICAL STUDY OF AD-214 APPROVED Key highlights: Human Research Ethics Committee (HREC) has approved Phase I extension...

Latest News